Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03126617|
Expanded Access Status : Available
First Posted : April 24, 2017
Last Update Posted : June 27, 2018
At BMS, we work with physicians/investigators to make investigational products available to patients with life-threatening diseases that have exhausted other treatment options and where there is a reasonable expectation of benefit over risk.
When contacted by a treating physician, BMS will consider requests for providing early patient access to Elotuzumab in patients with multiple myeloma who are residents of Belgium, Thailand, Turkey, Argentina, and Colombia.
|Condition or disease||Intervention/treatment|
|Multiple Myeloma||Biological: Elotuzumab|
Choosing to participate in an early patient access program is an important personal decision. Talk with your doctor and family members or friends about deciding to participate in an early patient access program.
To learn more about early patient access programs, your doctor may contact BMS using the information provided below.
|Study Type :||Expanded Access|
|Expanded Access Type :||Individual Patients|
|Official Title:||Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma|
- Biological: Elotuzumab
Elotuzumab (Emplicitii) is a Signaling Lymphocytic Activation Molecule Family member 7 (SLAMF7) directed immunostimulatory antibody approved by the US Food and Drug Administration (FDA) and indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Please contact your physician for more details.Other Names:
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03126617
|Contact: Bristol-Myers Squibb, Study Director||Please email:||Clinical.Trials@bms.com|
|Study Director:||Bristol-Myers Squibb||Bristol-Myers Squibb|